



The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS)

Ocena przydatności testu z gonadoliberyną (GnRH) w diagnostyce zespołu policystycznych jajników (PCOS)

Krzysztof C. Lewandowski^{1,2}, Agata Cajdler-Łuba², Ireneusz Salata^{2,3},
Małgorzata Bieńkiewicz⁴, Andrzej Lewiński^{1,2}

¹Department of Endocrinology and Metabolic Diseases, Medical University, Łódź, Poland

²Polish Mother's Memorial Hospital — Research Institute, Łódź, Poland

³Department of Diabetology and Metabolic Diseases, Medical University, Łódź, Poland

⁴Department of Quality Control and Radiation Protection Research, Medical University, Łódź, Poland

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is characterised by increased frequency of hypothalamic GnRH pulses leading to a relative increase in LH synthesis by the pituitary. As GnRH stimulation can reveal a relative LH excess, we have endeavoured to assess whether GnRH test might be useful in the diagnosis of PCOS.

Material and methods: The study involved 185 subjects: a PCOS group, n = 151, all with *oligo-* or *amenorrhoea*, aged (mean ± SD) 24.8 ± 5.4 years, BMI 24.5 ± 6.0 kg/m²; and regularly menstruating controls, n = 34, aged 26.6 ± 5.0 years, BMI 24.6 ± 5.5 kg/m². In 121 subjects with PCOS and in 32 controls, serum LH and FSH were measured before (0 minutes) and 30 and 60 minutes after GnRH stimulation (100 µg i.v.). Insulin resistance was assessed by HOMA and Insulin Resistance Index derived from glucose and insulin concentrations during 75 gram oral glucose tolerance test.

Results: Women with PCOS had higher testosterone (p = 0.0002), androstendione (p = 0.0021), 17OH-progesterone (p < 0.0001) and were more insulin resistant. Raised concentrations of at least one androgen were, however, found only in 58.1% of women with PCOS. Baseline and stimulated LH concentrations were higher in PCOS (9.09 ± 5.56 vs 4.83 ± 1.71 IU/L, 35.48 ± 31.4 vs 16.30 ± 6.68 IU/L, 33.86 ± 31.8 vs 13.45 ± 5.2 IU/L, at 0, 30 and 60 mins post GnRH, respectively, p < 0.0001). There was no difference in baseline or stimulated FSH concentrations between groups. Relative increases of LH or FSH in comparison to respective baseline values were similar in both groups. There was, however, a marked increase in LH/FSH ratio in PCOS in comparison to controls (LH_{0 min}/FSH_{0 min} 1.59 ± 0.95 vs 0.76 ± 0.2, LH_{30 min}/FSH_{30 min} 4.07 ± 3.0 vs 1.89 ± 0.79, LH_{60 min}/FSH_{60 min} 3.56 ± 2.58 vs 1.55 ± 0.63, p < 0.0001 at all time points). Further analysis revealed that LH_{30 min}/FSH_{30 min} > 2.11 or LH_{60 min}/FSH_{60 min} > 1.72 had 78.3% and 87.5% sensitivity and 81.7% and 81.3% specificity for the diagnosis of PCOS, respectively.

Conclusions: Women with PCOS have higher baseline and GnRH-stimulated LH concentrations. GnRH stimulation results in an increase in LH/FSH ratio in women with PCOS. Therefore we postulate that this phenomenon might be potentially useful as an additional tool in the diagnosis of PCOS. (*Pol J Endocrinol* 2011; 62 (2): 120–128)

Key words: polycystic ovary syndrome, GnRH test, insulin resistance, oligomenorrhoea

Streszczenie

Wstęp: Test z gonadoliberyną (GnRH) może ujawnić względną przewagę syntezy LH nad FSH, w wyniku zwiększonej częstości podwzgórzowych pulsów GnRH w zespole policystycznych jajników (PCOS, *polycystic ovary syndrome*). W pracy podjęto zatem próbę oceny, czy stymulacja przysadki przez GnRH może być przydatna w diagnostyce PCOS.

Materiał i metody: Badaniem objęto 185 osób: kobiety z PCOS, n = 151, z zaburzeniami miesiączkowania o typie *oligo-* lub *amenorrhoea*, w wieku (średnia ± SD) 24,8 ± 5,4 lat, wskaźnikiem masy ciała (BMI, *body mass index*) 24,5 ± 6,0 kg/m² oraz kobiety z grupy kontrolnej, n = 34, wiek 26,6 ± 5,0 lat, BMI 24,6 ± 5,5 kg/m². U 121 kobiet z PCOS oraz u 32 kobiet z grupy kontrolnej oznaczono LH i FSH przed (0 minut) oraz w 30 i 60 minut po podaniu GnRH (100 µg i.v.). Insulinooporność oceniono za pomocą modelu HOMA oraz za pomocą indeksu insulinooporności (IRI), obliczanego na podstawie stężeń glukozy i insuliny w doustnym teście tolerancji glukozy (75 g).

Wyniki: Kobiety z PCOS miały wyższe stężenia testosteronu całkowitego (p = 0,0002), androstendionu (p = 0,0021), 17OH-progesteronu (p < 0,0001) oraz charakteryzowały się większą insulinoopornością. Podwyższone stężenia któregoś z androgenów obserwowano u 58,1% kobiet z PCOS. Wyjściowe oraz stymulowane stężenia LH były wyższe u kobiet z PCOS (9,09 ± 5,56 v. 4,83 ± 1,71 IU/L, 35,48 ± 31,4 v. 16,30 ± 6,68 IU/L, 33,86 ± 31,8 v. 13,45 ± 5,2 IU/L, odpowiednio w 0, 30 i 60 minucie testu, p < 0,0001). Nie było różnic pomiędzy wyjściowymi oraz stymulowanymi stężeniami FSH między grupami. Stosunki stężeń LH oraz FSH po stymulacji przez GnRH w porównaniu z wartościami wyjściowymi były zbliżone w obu badanych grupach. Zaobserwowano znaczący wzrost stosunku LH/FSH u kobiet z PCOS, w porównaniu z grupami kontrolną (LH_{0 min}/FSH_{0 min} 1,59 ± 0,95 v. 0,76 ± 0,2, LH_{30 min}/FSH_{30 min} 4,07 ± 3,0 v. 1,89 ± 0,79, LH_{60 min}/FSH_{60 min}



Prof. Andrzej Lewiński MD, Department of Endocrinology and Metabolic Diseases Medical University, Polish Mother's Memorial Hospital — Research Institute, Rzgowska St. 281/289, 93-338 Łódź, Poland, tel.: +48 42 271 17 15, fax: +48 42 271 13 43, e-mail: alewin@csk.umed.lodz.pl

$3,56 \pm 2,58$ v. $1,55 \pm 0,63$, $p < 0,0001$ we wszystkich punktach czasowych). Stosunek $LH_{30 \text{ min}}/FSH_{30 \text{ min}} > 2,11$ lub $LH_{60 \text{ min}}/FSH_{60 \text{ min}} > 1,72$ charakteryzował się odpowiednio czułością 78,3% i swoistością 87,5% oraz czułością 81,7% i swoistością 81,3% dla kobiet z PCOS.

Wnioski: U kobiet z PCOS stwierdza się wyższe stężenia LH, zarówno przed, jak i po stymulacji przez GnRH. Stosunek stężeń LH do FSH ulega istotnemu zwiększeniu po stymulacji przez GnRH u kobiet z PCOS. Autorzy wnioskują, że ocena stosunku LH/FSH po stymulacji przez GnRH może być przydatna, jako badanie dodatkowe w diagnostyce PCOS.

(Endokryjol Pol 2011; 62 (2): 120–128)

Słowa kluczowe: zespół policystycznych jajników, test GnRH, insulinooporność, oligomenorrhea

Introduction

Polycystic ovary syndrome (PCOS) is the commonest endocrinopathy of women of reproductive age, affecting 4–7% of this population [1, 2]. Clinically it can present as oligo-/amenorrhoea, hyperandrogenism/hirsutism and/or fertility problems [1–3].

Current ESHRE/ASMR consensus defines PCOS by the so-called Rotterdam criteria [4]. According to these, PCOS can be diagnosed if a woman fulfills at least two of three criteria: i.e. oligo/anovulation, clinical or biochemical hyperandrogenism and/or polycystic ovaries on ultrasound imaging, when other causes of menstrual irregularities and hyperandrogenaemia have been ruled out [4]. In some cases, diagnosis of PCOS may be, however, still controversial, particularly in women with irregular periods and polycystic ovaries on ultrasound, but with androgens within the reference range. Increased androgen synthesis in PCOS, both of ovarian and adrenal origins [5], stems from abnormalities on several levels of the hypothalamo-pituitary-ovarian axis. The most prominent abnormality involves an increased frequency of pituitary LH pulses resulting from an increased frequency of pulsatile hypothalamic GnRH secretion. The above mentioned dysfunction of hypothalamic GnRH pulse generator leads to a relative increase of LH rather than FSH secretion by the pituitary [6], that in turn results in an increased LH-stimulated androgen secretion [7, 8]. More than 20 years ago, it was also noted that administration of a GnRH analogue allows the demonstration of abnormalities of ovarian steroidogenesis in PCOS, namely an increase of 17-hydroxy-progesterone to androstendione ratio after GnRH stimulation [9, 10]. On the strength of that, some authors [10, 11] formulated the concept of so-called *functional ovarian hyperandrogenism* that was supposed to be characteristic for PCOS and that could be demonstrated after stimulation by GnRH analogue (originally by nafarelin) [9–11]. The same authors [9–11] also described increased LH concentrations after GnRH analogue stimulation, but these changes were described in a qualitative, rather than a quantitative, manner. We have endeavoured to quantitatively investigate the issue of an increased LH release after GnRH stimulation.

Aim of the study

The aim of the study was to assess LH and FSH secretion after GnRH stimulation in women with PCOS, and in regularly menstruating healthy controls. We decided to compare both the changes in LH and FSH concentrations to their respective baseline values as well as the changes of LH/FSH ratio after GnRH stimulation. Thus, we have endeavoured to assess whether assessment of gonatrophin secretion after GnRH stimulation might provide some useful information for the diagnosis of PCOS.

Material and methods

The study involved 185 women admitted to the Department of Endocrinology & Metabolic Diseases of the 'Polish Mother' Memorial Research Institute and the Medical University of Lodz between 2006 and 2009. Of these, 151 women aged 24.8 ± 5.4 years (mean \pm SD) were diagnosed with PCOS according to the Rotterdam criteria [4]. All these women had had oligo- or amenorrhoea and polycystic ovaries on pelvic (intravaginal) ultrasound, while the majority also had clinical hyperandrogenism (acne and/or hirsutism). The control group consisted of 34 healthy, regularly menstruating, women aged 26.8 ± 5.0 years (Table I).

All hormonal investigations were performed between the third and sixth day of either a spontaneous or a progestagen-induced menstruation (in the latter case menstrual bleeding was typically obtained after ten-day administration of dydrogesterone (Duphaston®) or micronised progesterone (Luteina®). Endocrine investigations involved measurements of LH, FSH, oestradiol, total testosterone, androstendione, dihydroepiandrosterone sulphate (DHEAS), 17-hydroxyprogesterone, TSH, free T3 and free T4. The presence of hyperprolactinaemia was excluded after assessment of a nine time point prolactin day curve, as previously described [12]. Hypercortisolaemia was excluded either on the basis of a midnight serum cortisol below 50 nmol/L (1.8 μ g/dL) or on cortisol suppression below 50 nmol/L after an overnight 1.0 mg dexamethasone suppression test [13]. Furthermore, in all subjects we performed a 75 gram oral glucose tolerance test (OGTT) with glu-

Table I. Demographic characteristics of women with polycystic ovary syndrome (PCOS), $n = 151$, and regularly menstruating controls ($n = 34$)**Tabela I.** Statystyki opisowe dla danych demograficznych pacjentek z grupy kontrolnej ($n = 34$) i z PCOS ($n = 151$)

	Group	n	Mean	Median	SD	Min	Max	p value
Age (years)	PCOS	151	24.8	24.0	5.4	16.0	49.0	0.83
	CONTR	34	26.8	27.0	5.0	17.0	38.0	
BMI [kg/m ²]	PCOS	151	24.5	22.7	6.0	14.5	43.6	0.99
	CONTR	34	24.5	22.1	5.5	18.1	39.0	

Table II. Concentrations of selected hormones in women with PCOS and controls (CONTR)**Tabela II.** Stężenia badanych hormonów u pacjentek z PCOS i w grupie kontrolnej (CONTR)

	Group	n	Mean	Median	SD	Min	Max	p value
Oestradiol [pg/mL]	CONTR	32	45.49	35.09	31.69	12.05	190.4	0.018
	PCOS	151	65.31	47.60	62.06	15.0	406.7	
Testosterone [ng/mL]	CONTR	32	0.53	0.59	0.29	0.16	1.50	0.0002
	PCOS	151	0.77	0.72	0.40	0.20	2.07	
DHEAS [μg/dL]	CONTR	32	264.5	249.7	115.3	70.4	517.7	0.38
	PCOS	133	288.4	261.6	129.2	70.0	662.5	
Androstendione [ng/mL]	CONTR	31	2.23	2.15	0.93	0.79	5.04	0.0021
	PCOS	124	3.25	2.78	1.80	0.10	10.00	
17OH-progesterone [ng/mL]	CONTR	30	0.54	0.46	0.23	0.10	1.30	< 0.00001
	PCOS	120	1.25	1.00	0.93	0.30	6.29	

cose and insulin measurements at 0, 60 and 120 minutes. Subsequently, insulin resistance parameters were calculated, i.e. HOMA, (where $HOMA = \text{fasting insulin } (\mu\text{U/mL}) \times \text{fasting glucose (mmol/L)} / 22.5$) [14] and an Insulin Resistance Index (IRI) based on the assessment of glycaemia and insulinaemia during OGTT. The product of the glucose area under the plasma glucose curve and insulin area under plasma glucose curve is used as an index of insulin resistance, calculated through the formula: $2/[1/(\text{INSp} \times \text{GLYp})] + 1$, where INSp and GLYp are the measured insulin and glycaemic areas [15]. This method has a good correlation with the gold standard of assessment of insulin resistance, i.e. the euglycaemic hyperinsulinaemic clamp technique [16].

Hirsutism was assessed according to the Ferriman-Galwey scale [17], where a score above eight was considered significant. All pelvic ultrasound examinations were performed at the Department of Ultrasound Diagnostics of the 'Polish Mother' Memorial Research Institute, where diagnosis of polycystic ovaries was based on the presence of either 12 or more follicles measuring 2–9 mm in diameter, or increased ovarian volume ($> 10 \text{ cm}^3$) [18].

In 121 patients diagnosed with PCOS, and in 32 controls, we performed a GnRH test that involved intravenous administration of 100 μg of synthetic GnRH (Relisorm®) by Serono lub LHRH® by Ferring. Blood

samples for the measurements of LH and FSH (electrochemiluminescence method (ECLIA) by Elecsys 2010 analyser) were taken before (0 minutes) and 30 and 60 minutes after GnRH administration.

Statistical analysis

Depending on distribution characteristics of the analysed parameters, we employed either a *t*-test in cases of normal distribution or a Mann-Whitney test if distribution characteristics were not normal. Correlation analysis was performed by the means of Spearman rank correlation method. Statistical significance was assumed for $p < 0.05$. All analyses were performed using Statistica 8.0 software.

Results

Women with PCOS and regularly menstruating controls were matched for their age and BMI (Table I). Mean prolactin concentrations were higher in women with PCOS, but failed to reach statistical significance (data not shown). As expected, women with PCOS had higher concentrations of total testosterone, androstendione, 17-hydroxy-progesterone and oestradiol (Table II). It should be noted, however, that androgen concentrations remained within the reference range in a significant number of women with PCOS despite, on aver-

age, higher values than in controls. In particular, raised concentrations of total testosterone were noted only in 38.6% of women with PCOS, androstendione in 34.7% and DHEAS in only 28.8%. Raised concentration of at least a single androgen was observed in 58.1% of women with PCOS. Interestingly, women with PCOS also had significantly (i.e. around two-fold) higher 17-hydroxypregesterone/androstendione ratio. This was statistically highly significant ($p < 0.001$, see Fig. 1).

There were no differences in glucose levels during OGTT between women with PCOS and controls; women with PCOS had, however, higher concentrations of fasting insulin and were more insulin-resistant (IRI: 0.93 ± 0.38 v. 0.78 ± 0.34 , for PCOS and controls, respectively, $p = 0.045$). HOMA index was higher in women with PCOS, although this was of borderline statistical significance ($p = 0.06$) (Table III). Both baseline and GnRH-stimulated LH concentrations were significantly higher in women with PCOS, but there were no differences in FSH concentrations between women with PCOS and controls (Table IV, Fig. 2 and 3).

Relative proportions of GnRH-stimulated versus baseline gonadotrophin concentrations, i.e. $LH_{30\text{ min}}/LH_{0\text{ min}}$, $LH_{60\text{ min}}/LH_{0\text{ min}}$, $FSH_{30\text{ min}}/FSH_{0\text{ min}}$, $FSH_{60\text{ min}}/FSH_{0\text{ min}}$ were similar in PCOS and controls, though there was a trend towards higher $LH_{60\text{ min}}/LH_{0\text{ min}}$ ratio in women with PCOS (3.76 ± 2.0 IU/L v. 3.28 ± 2.59 IU/L, $p = 0.053$), Table V. In women with PCOS, we observed significantly raised LH/FSH ratio at all three time-points (Table V, Fig. 4). Furthermore, there was a further




Figure 1. 17-hydroxypregesterone [ng/mL] to androstendione [ng/mL] ratio in women with PCOS and controls

Rycina 1. Wskaźnik stosunku stężenia 17-OH-pregesteronu [ng/ml] do androstendionu [ng/ml] w u kobiet z PCOS i w grupie kontrolnej

increase in LH/FSH ratio after GnRH stimulation in women with PCOS (Table 5, Fig. 4), i.e. baseline LH/FSH ratio was 1.59 ± 1.0 in PCOS and 0.79 ± 0.2 in controls, but 4.09 ± 2.99 and 3.56 ± 2.58 for PCOS, and 1.89 ± 0.79 , and 1.55 ± 0.63 for controls at 30 and 60 minutes after GnRH stimulation, respectively ($p < 0.001$, Table V, Fig. 4).


Table III. Glucose, insulin and insulin resistance indices during oral glucose tolerance test (OGTT) in women with PCOS and controls (CONTR)

Tabela III. Glikemia, insulinemia w teście OGTT oraz wskaźniki insulinooporności u kobiet z PCOS i w grupie kontrolnej (CONTR)


	Group	n	Mean	Median	SD	Min	Max	p value
Glucose_0' [mg/dL]	PCOS	151	80.0	81.0	9.4	80.0	99.00	0.77
	CONTR	34	80.8	81.5	6.9	68.0	96.00	
Glucose_60' [mg/dL]	PCOS	145	112.6	109.0	36.1	140.0	242.0	0.93
	CONTR	34	112.6	113.0	31.0	93.0	213.0	
Glucose_120' [mg/dL]	PCOS	145	97.1	95.0	29.7	110.0	261.0	0.65
	CONTR	34	93.8	94.0	23.7	48.0	159.0	
Insulin_0' [mIU/mL]	PCOS	144	8.95	6.97	6.35	0.38	41.84	0.043
	CONTR	34	7.34	5.51	6.54	2.00	31.92	
Insulin_60' [mIU/mL]	PCOS	143	67.01	44.34	56.74	4.74	307.50	0.18
	CONTR	34	51.74	35.80	40.50	16.4	192.00	
Insulin_120' [mIU/mL]	PCOS	143	49.81	35.43	47.86	6.10	360.00	0.61
	CONTR	34	44.29	31.09	51.01	13.10	300.0	
IRI	PCOS	132	0.93	0.84	0.38	0.15	1.88	0.045
	CONTR	34	0.78	0.69	0.34	0.33	1.68	
HOMA [mmol/L × μIU/mL]	PCOS	144	1.81	1.41	1.36	0.37	8.37	0.060
	CONTR	34	1.48	1.16	1.32	0.36	5.99	

Table IV. Descriptive statistics for LH and FSH concentrations before and after GnRH stimulation in women with PCOS and controls**Tabela IV.** Statystyki opisowe parametrów LH i FSH w teście z GnRH u pacjentek z PCOS i w grupie kontrolnej

	Group	n	Mean	Median	SD	Min	Max	p value
LH_0' [IU/L]	PCOS	151	9.04	7.80	5.81	0.46	34.00	< 0.00001
	CONTR	34	4.83	4.57	1.68	1.08	922	
LH_30' [IU/L]	PCOS	121	35.38	24.00	31.32	5.92	200.00	< 0.00001
	CONTR	32	16.30	16.23	6.68	5.34	32.59	
LH_60' [IU/L]	PCOS	120	33.86	21.67	31.78	4.87	200.00	< 0.00001
	CONTR	32	13.45	12.79	5.22	5.01	28.51	
FSH_0' [IU/L]	PCOS	148	5.80	5.45	2.48	1.14	24.49	0.047
	CONTR	32	6.44	6.01	2.02	2.15	12.11	
FSH_30' [IU/L]	PCOS	121	8.90	7.83	4.84	3.24	42.58	0.312
	CONTR	32	8.84	8.11	2.73	3.61	15.28	
FSH_60' [IU/L]	PCOS	120	9.95	8.43	8.21	3.58	73.24	0.723
	CONTR	32	9.04	8.61	3.00	4.05	17.36	

**Figure 2.** Mean LH concentrations [IU/L] during GnRH test in women with PCOS and in regularly menstruating controls. Vertical bars represent 95% confidence intervals in the respective time-points

Rycina 2. Schematyczne przedstawienie rozkładów średnich wartości LH [jm./L] w teście z GnRH — w grupie z PCOS i w grupie kontrolnej. Pionowe słupki przedstawiają 95-procentowe przedziały ufności dla średnich wartości w odpowiednich punktach czasowych

**Figure 3.** Mean FSH concentrations [IU/L] during GnRH test in women with PCOS and in regularly menstruating controls. Vertical bars represent 95% confidence intervals in the respective time-points

Rycina 3. Schematyczne przedstawienie rozkładów średnich wartości poziomów FSH [jm./l] w teście z GnRH — w grupie z PCOS i w grupie kontrolnej. Pionowe słupki przedstawiają 95-procentowe przedziały ufności dla średnich wartości w odpowiednich punktach czasowych

Results of sensitivity and specificity analysis for LH/FSH ratio are presented in Table VI. Receiver operated characteristics analysis (ROC curves) was employed in order to define the best discriminatory cut-off point for GnRH-stimulated LH/FSH ratio. This revealed that $LH_{30\text{min}}/FSH_{30\text{min}} > 2.11$, or $LH_{60\text{min}}/FSH_{60\text{min}} > 1.72$, had 78.3% sensitivity and 87.5% specificity (for $LH_{30\text{min}}/FSH_{30\text{min}}$) as well as 81.7% sensitivity and 87.5% specificity ($LH_{60\text{min}}/FSH_{60\text{min}}$)

for diagnosis of PCOS (Fig. 5A and B). In contrast, baseline LH/FSH ratio above 2.0, although highly specific, had a very low sensitivity for the diagnosis of PCOS, i.e. only 23% (Table VI). Interestingly, ROC analysis for the baseline 17-hydroxy-progesterone to androstendione ratio demonstrated 68.4% sensitivity and 64.3% specificity for the diagnosis of PCOS for 17-hydroxy-progesterone [ng/mL]/androstendione [ng/mL] ratio > 0.244 .

Table V. Descriptive statistics for concentrations of LH and FSH in relation to their respective baseline values after GnRH stimulation and for the baseline LH/FSH ratio as well as LH/FSH ratio after GnRH stimulation in women with PCOS and controls (CONTR)

Tabela V. Statystyki opisowe stężeń LH i FSH w stosunku do wartości wyjściowych po stymulacji przez GnRH, oraz stosunku LH do FSH w teście z GnRH u pacjentek z PCOS i z grupy kontrolnej (CONTR)

	Group	n	Mean	Median	SD	Min	Max	p value
LH_30'/0'	PCOS	121	3.99	2.13	7.83	1.08	12.99	0.264
	CONTR	32	3.89	3.30	2.88	1.59	17.56	
LH_60'/0'	PCOS	120	3.76	3.06	2.00	1.10	11.89	0.053
	CONTR	32	3.28	2.78	2.59	0.94	15.91	
FSH_30'/0'	PCOS	121	1.52	1.41	0.53	0.81	5.80	0.211
	CONTR	32	1.38	1.33	0.21	1.08	1.98	
FSH_60'/0'	PCOS	120	1.68	1.47	1.14	0.86	12.96	0.061
	CONTR	32	1.42	1.39	0.25	0.96	2.13	
LH/FSH_0'	PCOS	121	1.59	0.99	1.00	0.23	5.28	< 0.00001
	CONTR	33	0.76	0.76	0.20	0.26	1.06	
LH/FSH_30'	PCOS	121	4.09	3.18	2.99	0.51	16.99	< 0.00001
	CONTR	32	1.89	1.75	0.79	0.72	5.25	
LH/FSH_60'	PCOS	120	3.56	2.77	2.58	0.43	13.65	< 0.00001
	CONTR	32	1.55	1.44	0.63	0.60	4.24	




Figure 4. Mean values of LH/FSH ratio during GnRH test in women with PCOS and in regularly menstruating controls. Vertical bars represent 95% confidence intervals in the respective time-points

Rycina 4. Schematyczne przedstawienie rozkładów średnich wartości stosunków LH/FSH w teście z GnRH — w grupie z PCOS i w grupie kontrolnej. Pionowe słupki przedstawiają 95-procentowe przedziały ufności dla średnich wartości w odpowiednich punktach czasowych

Discussion

The results of our study suggest that assessment of pituitary LH and FSH reserve after GnRH stimulation might be used to confirm the diagnosis of PCOS in some

Table VI. Sensitivity and specificity of diagnosis of PCOS based on selected cut-off points of baseline and GnRH-stimulated LH to FSH ratio

Tabela VI. Czulość i swoistość rozpoznania PCOS na podstawie oceny stosunku wyjściowego LH do FSH w teście z GnRH

LH/FSH ratio during GnRH test	Sensitivity (%)	Specificity (%)
LH/FSH_0' > 2.0	23	100
LH/FSH_30' > 2.11	78.3	87.5
LH/FSH_60' > 1.72	81.7	81.3
17-OHP/androstendione > 0.244	68.4	64.3

patients. The study was performed on a large number of women with PCOS, while the number of controls (matched for age and BMI) was similar to other leading studies on gonadotrophin secretion and GnRH stimulation in women with PCOS [10, 19, 20].

It is well known that relative proportions of pituitary secretion of LH and FSH are determined by both frequency and amplitude of hypothalamic GnRH pulses [20, 21]. Very frequent GnRH pulses (i.e. every 8–30 minutes) result in preferential transcription of proteins for alpha subunit. Pulse frequency of about 30–60 minutes results in preferential transcription of LH beta subunit, while less frequent pulses (i.e. every 120–240 minutes) lead to predominant transcription of FSH beta subunit [21]. In the normal menstrual cycle, GnRH pulse




Figure 5. Receiver operating characteristics (ROC) curve analysis for finding the cut-off for optimal diagnostic accuracy (considered as the highest proportion of correctly classified subjects) of LH/FSH ratio during GnRH test. The highest sensitivity (78.3% and 81.3%) is obtained for LH/FSH > 2.110 at 30 minutes of GnRH test (A) and for LH/FSH > 1.723 at 60 minutes of GnRH test (B). Respective sensitivity is 87.5% and 81.3%. A. ROC curve for assessment of cut-off point for maximal sensitivity for LH/FSH ratio at 30 minutes of GnRH test; B. ROC curve for assessment of cut-off point for maximal sensitivity for LH/FSH ratio at 60 minutes of GnRH test

Rycina 5. Analiza optymalnej czułości oceny stosunku stężeń LH do FSH w teście z GnRH dla optymalnej swoistości. Najwyższa czułość diagnostyczna (odpowiednio 78,3% i 81,7%) jest osiągnięta dla stosunku LH/FSH > 2,110 w 30. minucie testu (A) oraz dla stosunku LH/FSH > 1,723 w 60. minucie testu z GnRH (B). Odpowiednio swoistość wynosi 87,5 i 81,3%. A. Ocena punktu odcięcia dla maksymalnej czułości testu z GnRH dla stosunku LH/FSH w 30. minucie testu z GnRH (krzywa ROC); B. Ocena punktu odcięcia dla maksymalnej czułości testu z GnRH dla stosunku LH/FSH w 60. minucie testu z GnRH (krzywa ROC)

frequency increases from about 90-100 minutes to about every 60 minutes through a follicular phase. Gradual increase in GnRH pulse frequency facilitates LH secretion culminating in an ovulatory LH surge [22, 23]. In contrast, increased progesterone secretion in a luteal phase results in an increase in FSH synthesis as a result of less frequent hypothalamic GnRH secretion (approximately one pulse every 3-5 hours), through mechanisms involving opioid receptors [24-27] and possibly other factors such as kisspeptin [28].

PCOS is characterised by an increase in both frequency and amplitude of hypothalamic GnRH pulses, generated at a frequency of about once every 60 minutes, i.e. the frequency observed only in the late follicular phase in healthy women [29, 30]. This is accompanied by resistance to inhibitory effects of progesterone on the frequency of hypothalamic GnRH secretion [31, 32]. Furthermore, a similar situation has been observed in hyperandrogenic adolescent girls even in the setting of regular menstrual cycles [33, 34].

As a result of the above described phenomena, PCOS is characterised by a relative overproduction of LH in relation to FSH. Hence, an increased LH to FSH ratio was once suggested to be used as an additional param-

eter confirming the diagnosis of polycystic ovary syndrome [6, 35]. There was, however, no agreement as to the optimal cut-off point for the baseline LH to FSH ratio, and various authors suggested various cut-off values (e.g. LH/FSH > 1 [36], LH/FSH > 2 [37] or even LH/FSH > 3 [38]). Meta-analysis of several studies demonstrated, however, very poor positive predictive value for baseline LH/FSH ratio i.e. only 18% [39], which effectively precluded the use of this index as a valid diagnostic tool. In our series, 74% of women with PCOS had higher baseline LH than FSH concentrations, but for the most frequently quoted cut-off point of LH/FSH > 2 [37] we obtained only a 23% sensitivity (and 43% sensitivity for LH/FSH > 1.5), despite high (100%) specificity for the diagnosis of PCOS.

In such circumstances, there is a question as to why the sensitivity of baseline LH/FSH ratio is so low despite evidence for increased LH synthesis in PCOS. As it turns out, women with PCOS, as well as more pronounced insulin resistance and hyperandrogenism, have relatively lower LH concentrations [20, 40-44], despite preserved increased GnRH pulse frequency in those who are more obese and insulin-resistant [42]. The same phenomenon was also observed in our study,

where there was a weak ($r = -0.21$), but still significant ($p < 0.05$) correlation between BMI and baseline LH concentrations as well as between LH and insulin resistance index ($r = -0.31$).

In our study, a relative increase of LH concentrations is proportional to (higher) baseline LH concentrations in women with PCOS, resulting in higher stimulated LH concentrations in this group, albeit without significant differences in either baseline or stimulated FSH levels. This is in accordance with results of other studies [20, 45]. Such a situation results in a more pronounced increase of GnRH-stimulated LH/FSH ratio in women with PCOS than in controls. This, in turn, leads to a dramatic (almost four-fold) increase in the diagnostic sensitivity of GnRH-stimulated LH/FSH ratio. For instance, results of ROC analysis reveal 81.7% sensitivity with 81.3% specificity for LH/FSH ratio above 1.72 post GnRH stimulation. This is much better than sensitivity of total testosterone assays (around 40% [46]) and is even higher than the sensitivity of all androgen analyses (58.1%) observed in our study. One must be also aware that assessment of androgen concentrations within the female range by the means of standard androgen assays is fraught with methodological problems, including very high coefficients of variation reaching as much as around 35% [47–49], while the more accurate mass spectrometry method [50] is still very rarely used in Poland. If such assay-dependent variability were employed e.g. for the diagnosis of diabetes, than for fasting glucose concentration of 136 mg/dL, the obtained results would range from 88 mg/dL (entirely normal) to as much as 183 mg/dL (poorly controlled diabetes)!

According to the current consensus [4], diagnosis of PCOS requires exclusion of other causes of oligo-/amenorrhoea and hyperandrogenism (e.g. hyperprolactinaemia, hypercortisolaemia, late-onset congenital adrenal hyperplasia). In such a context, we note that in our study more than 40% of the women with PCOS according to the Rotterdam criteria [4] had androgens within the reference range i.e. on the basis of coexistence of oligo/amenorrhoea and polycystic ovaries, they would not be classified as having PCOS according to the recent Androgen Excess Society criteria [51].

We suggest that assessment of GnRH-stimulated LH/FSH ratio may be potentially useful, particularly in that group of women.

As we have already described, Barnes et al. [9] and Ehrmann et al. [10] have suggested that the GnRH test might be useful in the diagnosis of PCOS, but the issue of the optimal GnRH test protocol remains unresolved. In particular, there is a question whether GnRH test should be performed according to the protocol involving assessment of 17-hydroxy-progesterone/androstendione ratio around 24-hours post GnRH agonist stimu-

lation, as described before [9, 10]. As it turns out, however, increased GnRH stimulated 17-hydroxy-progesterone/androstendione ratio is observed only in slightly less than 50% of women with PCOS [52]. That is also in accordance with earlier studies involving ovarian and adrenal vein catheterisation [5], where frank ovarian hyperandrogenism was observed in only around 50% (10/21) of women with PCOS. Interestingly this is slightly lower than the diagnostic utility of baseline 17-hydroxy-progesterone/androstendione ratio above 0.244 (ROC analysis) observed in our study, where we observed 68.4% sensitivity and 64.3% specificity for the diagnosis of PCOS.

In summary, our study demonstrated a marked increase in GnRH-stimulated LH/FSH ratio in women with PCOS diagnosed according to the Rotterdam criteria [4]. Although the results of our study need to be confirmed in women with hyperandrogenism, polycystic ovaries and regular menses, we suggest that assessment of GnRH stimulated LH/FSH ratio might be potentially useful as a confirmatory test for the diagnosis of PCOS in some patients, such as women with polycystic ovaries and oligo-/amenorrhoea, but with androgens within the reference range. In such cases, LH/FSH ratio above 2.11 at 30 minutes post GnRH stimulation, or above 1.72 at 60 minutes post GnRH stimulation, would support a diagnosis of PCOS.

References

1. Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004; 89: 2745–2749.
2. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med* 2005; 352: 1223–1236.
3. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. *Clin Endocrinol (Oxf)* 1989; 30: 459–470.
4. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. *Human Reprod* 2004; 19: 41–47.
5. Milewicz A, Silber D, Mielecki T. The origin of androgen synthesis in polycystic ovary syndrome. *Obstet Gynecol* 1983; 62: 601–614.
6. Taylor AE, McCourt B, Martin KA et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1997; 82: 2248–2256.
7. Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. *Human Reprod Update* 2006; 12: 351–361.
8. Rosenfield RL. Identifying children at risk for polycystic ovary syndrome. *J Clin Endocrinol Metab* 2007; 92: 787–796.
9. Barnes RB, Rosenfield RL, Burstein S et al. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. *N Engl J Med* 1989; 320: 559–565.
10. Ehrmann DA, Rosenfield RL, Barnes RB et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. *N Engl J Med* 1992; 327: 157–162.
11. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. *Endocrine Rev* 1995; 16: 322–353.
12. Karasek M, Pawlikowski M, Lewiński A. Hyperprolactinemia: causes, diagnosis, and treatment. *Endokrynol Pol* 2006; 57: 656–662.
13. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. *J Clin Endocrinol Metab* 2003; 88: 5593–5602.

14. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–419.
15. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. *Mol Genet Metab* 1998; 63: 134–141.
16. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. *Diabetes Care* 1999; 9: 1462–1470.
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol. Metab* 1961; 21: 1440–1447.
18. Balen AH, Laven JS, Tan SL et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. *Hum Reprod Update* 2003; 9: 505–514.
19. Rosenfield RL, Ehrmann DA, Barnes RB et al. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. *Ann N Y Acad Sci* 1993; 687: 161–181.
20. Lawson MA, Jain S, Sun S et al. Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. *J Clin Endocrinol Metab* 2008; 93: 2089–2096.
21. Ferris HA, Shupnik MA. Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GnRH1. *Biol Reprod* 2006; 74: 993–998.
22. Marshall JC, Dalkin AC, Haisenleder DJ et al. Gonadotropin releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. *Rec Prog Horm Res* 1991; 47: 155–187.
23. Marshall JC, Eagleson CA. Neuroendocrine aspects of polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1999; 28: 295–324.
24. Nippoldt TB, Reame NE, Kelch RP et al. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. *J Clin Endocrinol Metab* 1989; 69: 67–76.
25. Romano GJ, Krust A, Pfaff DW. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study. *Mol Endocrinol* 1989; 3: 1295–1300.
26. Soules MR, Steiner RA, Clifton DK et al. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. *J Clin Endocrinol Metab* 1984; 58: 378–383.
27. Berga SL, Yen SS. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1989; 30: 177–184.
28. Neal-Perry G, Lebesgue D, Lederman M et al. The excitatory peptide kisspeptin restores the luteinizing hormone surge and modulates amino acid neurotransmission in the medial preoptic area of middle-aged rats. *Endocrinology* 2009; 150: 3699–3708.
29. Kazer RR, Kessel B, Yen SS. LH pulse frequency in women with PCO. *J Clin Endocrinol Metab.* 1987; 65: 233–236.
30. Waldstreicher J, Santoro NF, Hall JE et al. Hyperfunction of the hypothalamic pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. *J Clin Endocrinol Metab* 1988; 66: 165–172.
31. Carmen LP, Griffin-Korf ML, Aloï JA et al. Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. *J Clin Endocrinol Metab* 1998; 83: 582–590.
32. Blank SK, McCartney CR, Chhabra S et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls — implications for regulation of pubertal maturation. *J Clin Endocrinol Metab* 2009; 94: 2360–2366.
33. Apter D, Butzow T, Laughlin GA et al. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovary syndrome. *J Clin Endocrinol Metab* 1994; 79: 119–125.
34. Chabra S, McCartney CR, Yoo RY et al. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenic adolescent girls. *J Clin Endocrinol Metab* 2005; 90: 2810–2815.
35. Taylor AE. Polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1998; 27: 877–902.
36. Stewart PM, Penn R, Holder R et al. The hypothalamo-pituitary-adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1993; 38: 387–391.
37. Koskinen P, Penttilä T, Anttila L et al. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. *Fertil Steril* 1996; 65: 517–522.
38. Jasonni VM, Bulletti C, Naldi S et al. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17-b-estradiol. *Fertil Steril* 1991; 55: 742–745.
39. Barth JH, Yasmin E, Balen AH. The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. *Clin Endocrinol (Oxf)* 2007; 67: 811–815.
40. Arroyo A, Laughlin GA, Morales AJ et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. *J Clin Endocrinol Metab* 1997; 82: 3728–3733.
41. Morales AJ, Laughlin GA, Butzow T et al. Insulin, somatotrophic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. *J Clin Endocrinol Metab* 1996; 81: 2854–2864.
42. Dale PO, Tanbo T, Vaaler S et al. Body weight, hyperinsulinaemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. *Fertil Steril* 1992; 58: 487–491.
43. Ke WX, Shan GQ, Hua SY. Different responses of insulin, C-peptide, and testosterone to an oral glucose tolerance test in two groups of women with polycystic ovarian syndrome. *Acta Obstet Gynecol Scand* 1996; 75: 166–169.
44. Banaszewska B, Spaczyński RZ, Pelesz M et al. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinaemia. *Rocz Akad Med Białymst* 2003; 48: 131–134.
45. Patel K, Cofferr MS, Dahan MH et al. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 2004; 60: 67–74.
46. Balen AH, Conway GS, Kaltsas G et al. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. *Hum Reprod* 1995; 10: 2705–2712.
47. Barth JH. What service does the laboratory provide? *Endocrine Abstracts* 2009; 19: S46.
48. Fears TR, Ziegler RG, Donaldson JL et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. *Cancer Epidemiol Biomarkers Prev.* 2000; 9: 403–412.
49. Boots LR, Potter S, Potter D et al. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. *Fertil Steril.* 1998; 69: 286–292.
50. Vesper HW, Bhasin S, Wang C et al. Interlaboratory comparison study of serum total testosterone measurements performed by mass spectrometry methods. *Steroids* 2009; 74: 498–503.
51. Azziz Z, Carmina E, Dewailly D et al. Androgen Excess Society 2006 Positions Statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab* 2006; 91: 4237–4245.
52. Pasquali R, Patton L, Pocognoli P et al. 17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. *J Clin Endocrinol Metab* 2007; 92: 4208–4217.